Pyxis Oncology is trading 14% up today at $2.98, moving in tandem with a broad rally in biotechnology shares rather than on new company-specific developments.
- The advance is attributed to renewed risk appetite and sector-wide strength, fueled by blockbuster M&A activity and positive clinical trial data from other industry players.
- While the stock has been highly volatile, it maintains strong 30-day performance as investors rotate back into the biotech space.